Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results

Solvej Lippert, Kasper D Berg, Gunilla Høyer-Hansen, Ida K Lund, Peter Iversen, Ib J Christensen, Klaus Brasso, Martin A Røder

    11 Citations (Scopus)


    AIM: Urokinase plasminogen activator receptor (uPAR) plays a central role during cancer invasion by facilitating pericellular proteolysis. We initiated the prospective 'Copenhagen uPAR Prostate Cancer' study to investigate the significance of uPAR levels in prostate cancer (PCa) patients.

    METHODS: Plasma samples and clinical data from patients with newly diagnosed PCa have been collected prospectively. The uPAR forms have been measured in plasma using time-resolved fluorescence immunoassays.

    RESULTS: The level of intact uPAR(I-III) did not differ. Plasma uPAR(I-III) + uPAR(II-III) levels and uPAR(I) levels were significantly higher in hormone-naive and castrate-resistant patients compared with patients with localized disease (both: p < 0.0001).

    CONCLUSION: Our results show that cleaved uPAR forms are significantly increased in patients with advanced PCa.

    Original languageEnglish
    JournalBiomarkers in Medicine
    Issue number2
    Pages (from-to)209-16
    Number of pages8
    Publication statusPublished - Feb 2016


    Dive into the research topics of 'Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results'. Together they form a unique fingerprint.

    Cite this